グリベンクラミドとカボチャの種エキスの抗糖尿病効果の強化: コンピューティングおよびインビボプロファイリングからの洞察
Bhoomika H R1, Anil Kumar K V1, Vachana M N1
1Department of Pharmacology, Visveswarapura Institute of Pharmaceutical Sciences, Banashankari II Stage, Bengaluru, 560070 India.
In silico pharmacology
|February 20, 2026
まとめ
グリベンクラミドと組み合わせた南瓜の種抽出物は,ネズミで相乗効果の抗糖尿病効果を示しています. この組み合わせ療法は,血糖を効果的に管理し,全体的な健康状態を改善し,糖尿病治療の潜在的な補助剤を示唆しています.
科学分野:
- 薬理学と毒理学について
- 自然製品に関する研究
- メタボリック疾患
背景:
- 長期にわたる糖尿病治療は,従来の薬剤の潜在的な副作用のために,代替アプローチを必要とします.
- パンプキンシードは伝統的な抗糖尿病剤の性質を持っていますが,グリベンクラミドのような従来の薬との相互作用は調査が必要です.
研究 の 目的:
- グリベンクラミドと組み合わせたエタノールカボチャ種エキスの潜在的相互作用と相乗効果の抗糖尿病効果を評価する.
- In-silico方法を使用してカボチャ種子植物成分のマルチターゲティングの可能性を調査する.
主な方法:
- ネットワーク薬理学,遺伝子本体学,分子ドッキングを含むインシリコ分析が行われました.
- ストレプトゾトシン誘発型糖尿病のラットは,南瓜種エキス,グリベンクラミド,またはその組み合わせを28日間投与した.
- 生物化学的パラメータ (血糖,脂質プロファイル,HbA1c,インスリン,腎臓のバイオマーカー) と組織病理学が評価されました.
主要な成果:
- In-silico分析により,南瓜種子化合物の糖尿病関連の主要標的が特定されました.
- 併用療法は,体重,血糖コントロール,グルコース耐性,脂質/腎臓プロフィールの有意な改善を示した.
- 組織学的検査により,治療を受けたグループでは,臓,肝臓,腎臓の整体性が保たれていることが明らかになった.
結論:
- カボチャ種子エタノール抽出物とグリベンクラミドは,相乗効果の抗糖尿病効果を示しています.
- 組み合わせ治療は,糖尿病とその合併症の管理に有効な補助剤として有望であることが示されています.
- パンプキンシードの植物成分は,糖尿病に関連する経路に対してマルチターゲティングの可能性を持っています.
関連する概念動画
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K


